Bankrupt genetic-testing firm 23andMe agreed to sell its data bank, which once contained DNA samples from about 15 million people, to the drug developer Regeneron Pharmaceuticals for $256 million. The ...
Opinion
18hon MSNOpinion
‘The company failed to implement basic defenses’: 23andMe data breach victims are finally getting paid, but bankruptcy could shrink their payouts
The settlement highlights the lasting risks of exposing genetic data that can’t be changed or replaced.
23andMe compiles genetic profiles of people through DNA testing kits, but it was heavily criticised after a 2023 hack.
DNA company 23andMe owes customers $47 million as part of a settlement. See if you're eligible for this payment ...
Tarrytown-based Regeneron would acquire 23andMe for $256 million under the deal that is pending approval by bankruptcy court and regulators. New York-based biotech giant Regeneron Pharmaceuticals ...
Remember when everyone was discovering they were 12% Scandinavian and posting colorful pie charts of their genetic heritage on social media? Those glory days of DNA testing have come to a stunning end ...
Following a data breach and bankruptcy, genetic testing service 23andMe will soon be in different hands. On Monday, biotechnology company Regeneron announced that it won the top bid in a bankruptcy ...
The founder of 23andMe Research Institute wants to reach 100 million users, an ambitious goal after the seller of DNA testing kits emerged from bankruptcy as a nonprofit. 23andMe has the DNA of about ...
A nonprofit controlled by Anne Wojcicki, former chief executive of 23andMe, has won the bidding process to buy the bankrupt genetic testing company. If approved by the court, the sale would put ...
Valerie is a seasoned writer and editor who has spent her career creating content in the parenting and women's wellness spaces. Before joining Forbes Health, Valerie was the trending news editor at ...
Bankrupt genetic-testing firm 23andMe has agreed to sell its data bank, which once contained DNA samples from about 15 million people, to the drug developer Regeneron Pharmaceuticals for $256 million.
Bankrupt genetic-testing firm 23andMe agreed to sell its data bank, which once contained DNA samples from about 15 million people, to the drug developer Regeneron Pharmaceuticals for $256 million. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results